AllergyNCT01634516
Effectiveness of Mediterranean Diet Intervention in Pregnant Women
A study testing Dietary support and No dietary support in people with Allergy, run by Heriot-Watt University at 2 sites in United Kingdom.
Trial summary
There has been an increase in asthma and allergic disease prevalence, especially in children. Given the high prevalence, and the associated high disease burden and costs, there is an urgent need to identify effective strategies for the primary prevention of asthma and allergy. Read more about this study
- Who is it for?
- Ages 16 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Allergy
- What is being tested?
- Dietary support and No dietary support
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- May 2012to Aug 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Pregnant in first trimester
- Age 16 years and above
- One or more first degree blood relatives of the baby with atopic dermatitis(eczema), food allergy, allergic rhinitis (persistent or intermittent) or asthma
- Willing to give informed consent
Who cannot join
- Age <16 years
- No first degree blood relatives of the baby with atopic dermatitis (eczema), food allergy, allergic rhinitis (persistent or intermittent) or asthma
- Recent (within the last 3 months) or current involvement in a dietary or supplementation trial
- Unable to give informed consent
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Leith Community Treatment Centre
Edinburgh, Scotland
St John's Hospital
Livingston, Scotland, EH54 6PP
About this study
Official title: An Investigation of the Effectiveness of the Mediterranean Diet in Pregnant Women at Risk of Developing Allergy in Their Infants: Pilot Randomised Controlled Trial
There has been an increase in asthma and allergic disease prevalence, especially in children. Given the high prevalence, and the associated high disease burden and costs, there is an urgent need to identify effective strategies for the primary prevention of asthma and allergy. A systematic review of the literature has found strong supportive epidemiological evidence of a protective role for the Mediterranean Diet (MD).
The investigators aim is to undertake a pilot trial in a sample of pregnant women to establish recruitment, retention, a measurable change to a dietary intervention encouraging greater adherence to a MD during pregnancy, and acceptability of the dietary advice and diet modifications.
Read more
This pilot study will be a 2-arm randomised controlled trial (RCT) in a sample population of around 50 Scottish pregnant women.
This work ultimately aims to contribute to improving health outcomes through seeking to reduce the incidence of asthma and allergic problems. This pilot trial will prove invaluable in informing the subsequent planned definitive parallel group RCT.
Read the detailed description
Aims
The primary aims of this pilot trial are to investigate rates of maternal recruitment and retention, and adherence with a MD during the latter two trimesters of pregnancy (i.e. weeks 12 to 36). The secondary aims are to determine whether there is any subsequent measurable change in the Mediterranean Diet score and whether the dietary advice and diet modifications are acceptable.
Research questions
- What are the recruitment and retention rates of pregnant mothers whose infants are at high risk of atopic disease?
- Is the advice and dietary modification acceptable to participants?
- To what extent are mothers able to adhere to a MD?
- Can a MD score be increased in pregnancy?
- Can a measurable change in a biomarker of oxidative stress be detected as a result of adherence to a MD?
- Can any increases in MD be sustained during pregnancy?
Design
- Trial design This is a two-arm pilot RCT. Trial participants will be recruited from 2-3 hospitals/community treatment centres in Scotland.
- Participant recruitment Pregnant women aged 16 years and above will be sent a letter of invitation, information for participants, and a consent form for the trial with their dating scan appointment by the hospital. Interested participants will be invited to contact the researcher by text, phone or email to discuss the project and answer any questions they may have; they will then be screened for eligibility to take part in the trial. Eligibility of high risk women is defined as: those with one or more first degree blood relatives with atopic dermatitis (eczema), a food allergy, allergic rhinitis (hay fever) or asthma, using the question 'Do you, the mother, or the father or sibling of the baby have an allergic disease: eczema, a food allergy, hay fever or asthma?' Responses will be recorded on the screening questionnaire. The researcher will send to the participant a food frequency questionnaire for completion at home and a urine container with instructions to fill the container on the day of the scan and bring it, with the Consent form and the completed FFQ along with them to hand over to the researcher. The urine specimen will be used for the analysis of markers of oxidative stress, antioxidant activity and nitric oxide (NO) synthesis. The researcher will greet the participant in the waiting area of the clinic prior to their dating scan where their consent form, urine sample and FFQ will be collected. After their scan, consenting eligible participants will complete a baseline MD questionnaire.
- Intervention The intervention is a 15 minute dietary advice session directed at increasing the MD score, with subsequent telephone support sessions throughout the pregnancy. Intervention arm Mothers randomised to the intervention arm will meet with the project researcher when visiting the hospital for their first dating scan. After the scan, participants will receive a 15 minute dietary advice session, encouraging the consumption of particular foods that are consistent with the MD, and the key messages will be supplemented through written/visual materials, and through regular supportive telephone calls. No energy restrictions will be suggested. A £10 supermarket voucher will be given to the participants. The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD questionnaire to inform them they will receive the second MD questionnaire and reply envelope for completion and return. A further supermarket voucher to the value of £10 will be sent to the participant on receipt of the completed form. Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher will contact participants by phone and arrange a home visit. When visited at home by the researcher, a third MD questionnaire and second FFQ will be completed and handed to the researcher and a urine sample will be obtained. Free and continuous telephone access to the researcher will be available throughout the study. Control arm Mothers randomised to the control arm will meet with the project researcher when visiting the hospital for their first dating scan. The participant will not receive the 15 minute dietary advice session. A £10 supermarket voucher will be given to the participants. The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD questionnaire to inform them they will receive the second MD questionnaire and reply envelope for completion and return. A further supermarket voucher to the value of £10 will be sent to the participant on receipt of the completed form. Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher will contact participants by phone and arrange a home visit. When visited at home by the researcher, a third MD questionnaire and second FFQ will be completed and handed to the researcher and a urine sample will be obtained.
- Randomisation Allocation to the intervention or control arm will be via pre-randomised sealed envelopes, based on a predetermined random number allocation, restricted by recruitment site. This restricted randomisation will be carried out by an independent statistician.
- Follow-up Participants will be enrolled for a total of ~7 months (i.e. from 12-36 weeks of pregnancy).
Outcome measures
- Recruitment rate (i.e. the proportion of those invited to take part compared with the number of consenting women)
- Retention rate (i.e. the proportion of those starting the study to those finishing)
- Change in MD score from baseline to 24 and 36 weeks of pregnancy
- Change in oxidative stress and whole-body NO production
- Acceptability of dietary advice and diet modifications
- Conditions
- Allergy
- Being tested
- Dietary support, No dietary support
- Keywords
- Diet, Pregnant
- Medical subject headings
- Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary supportBehavioural
Face to face intervention plus subsequent telephone support
No dietary supportBehavioural
No face to face intervention or subsequent telephone support
| Study group | Role | What they receive |
|---|---|---|
| Dietary support | Experimental | Face to face intervention plus subsequent telephone support Receives: Behavioral: Dietary support |
| No dietary support | Placebo comparator | No face to face intervention plus subsequent telephone support Receives: Behavioral: No dietary support |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment rate of pregnant mothers whose infants are at high risk of atopic disease.
Measured: 4 months
Secondary outcomes (1)
Mediterranean Diet score in pregnancy
Measured: 12 and 24 weeks post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2012 (estimated)
- Study startMay 2012
- Primary completionJul 2013
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Heriot-Watt University
- Sponsor type
- University, hospital or other
- Collaborators
- University of Edinburgh
- Responsible party
- Principal investigator, Dean A. Sewell, Heriot-Watt University
- Investigators
- Dean A. Sewell, PhD, Principal investigator, Heriot-Watt UniversityAziz Sheikh, MBBS, MD, Study chair, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01634516
- Sponsor's protocol ID
- HWU113821/UoE
- Other IDs
- CZG/2/558
- Status last verified
- Aug 2017
- First submitted
- 3 Jul 2012
- Last updated
- 14 Aug 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Sewell DA, Hammersley VS, Devereux G, Robertson A, Stoddart A, Weir C, Worth A, Sheikh A. Investigating the effectiveness of the Mediterranean diet in pregnant women for the primary prevention of asthma and allergy in high-risk infants: protocol for a pilot randomised controlled trial. Trials. 2013 Jun 14;14:173. doi: 10.1186/1745-6215-14-173.
PubMed 23768094Sewell DA, Hammersley VS, Robertson A, Devereux G, Stoddart A, Weir CJ, Worth A, Sheikh A. A pilot randomised controlled trial investigating a Mediterranean diet intervention in pregnant women for the primary prevention of allergic diseases in infants. J Hum Nutr Diet. 2017 Oct;30(5):604-614. doi: 10.1111/jhn.12469. Epub 2017 Feb 16.
PubMed 28211106
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Investigation of the Effectiveness of the Mediterranean Diet in Pregnant Women at Risk of Developing Allergy in Their Infants: Pilot Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT01634516
- Acronym / sponsor ID
- HWU113821/UoE
- Conditions
- Allergy
- Keywords
- Diet, Pregnant
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Heriot-Watt UniversityUniversity, hospital or other
- Collaborators
- University of Edinburgh
- Study start
- May 2012
- Primary completion
- Jul 2013 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 6 Jul 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There has been an increase in asthma and allergic disease prevalence, especially in children. Given the high prevalence, and the associated high disease burden and costs, there is an urgent need to identify effective strategies for the primary prevention of asthma and allergy. A systematic review of the literature has found strong supportive epidemiological evidence of a protective role for the Mediterranean Diet (MD).
The investigators aim is to undertake a pilot trial in a sample of pregnant women to establish recruitment, retention, a measurable change to a dietary intervention encouraging greater adherence to a MD during pregnancy, and acceptability of the dietary advice and diet modifications.
This pilot study will be a 2-arm randomised controlled trial (RCT) in a sample population of around 50 Scottish pregnant women.
This work ultimately aims to contribute to improving health outcomes through seeking to reduce the incidence of asthma and allergic problems. This pilot trial will prove invaluable in informing the subsequent planned definitive parallel group RCT.
Detailed description
Aims
The primary aims of this pilot trial are to investigate rates of maternal recruitment and retention, and adherence with a MD during the latter two trimesters of pregnancy (i.e. weeks 12 to 36). The secondary aims are to determine whether there is any subsequent measurable change in the Mediterranean Diet score and whether the dietary advice and diet modifications are acceptable.
Research questions
- What are the recruitment and retention rates of pregnant mothers whose infants are at high risk of atopic disease?
- Is the advice and dietary modification acceptable to participants?
- To what extent are mothers able to adhere to a MD?
- Can a MD score be increased in pregnancy?
- Can a measurable change in a biomarker of oxidative stress be detected as a result of adherence to a MD?
- Can any increases in MD be sustained during pregnancy?
Design
- Trial design This is a two-arm pilot RCT. Trial participants will be recruited from 2-3 hospitals/community treatment centres in Scotland.
- Participant recruitment Pregnant women aged 16 years and above will be sent a letter of invitation, information for participants, and a consent form for the trial with their dating scan appointment by the hospital. Interested participants will be invited to contact the researcher by text, phone or email to discuss the project and answer any questions they may have; they will then be screened for eligibility to take part in the trial. Eligibility of high risk women is defined as: those with one or more first degree blood relatives with atopic dermatitis (eczema), a food allergy, allergic rhinitis (hay fever) or asthma, using the question 'Do you, the mother, or the father or sibling of the baby have an allergic disease: eczema, a food allergy, hay fever or asthma?' Responses will be recorded on the screening questionnaire. The researcher will send to the participant a food frequency questionnaire for completion at home and a urine container with instructions to fill the container on the day of the scan and bring it, with the Consent form and the completed FFQ along with them to hand over to the researcher. The urine specimen will be used for the analysis of markers of oxidative stress, antioxidant activity and nitric oxide (NO) synthesis. The researcher will greet the participant in the waiting area of the clinic prior to their dating scan where their consent form, urine sample and FFQ will be collected. After their scan, consenting eligible participants will complete a baseline MD questionnaire.
- Intervention The intervention is a 15 minute dietary advice session directed at increasing the MD score, with subsequent telephone support sessions throughout the pregnancy. Intervention arm Mothers randomised to the intervention arm will meet with the project researcher when visiting the hospital for their first dating scan. After the scan, participants will receive a 15 minute dietary advice session, encouraging the consumption of particular foods that are consistent with the MD, and the key messages will be supplemented through written/visual materials, and through regular supportive telephone calls. No energy restrictions will be suggested. A £10 supermarket voucher will be given to the participants. The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD questionnaire to inform them they will receive the second MD questionnaire and reply envelope for completion and return. A further supermarket voucher to the value of £10 will be sent to the participant on receipt of the completed form. Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher will contact participants by phone and arrange a home visit. When visited at home by the researcher, a third MD questionnaire and second FFQ will be completed and handed to the researcher and a urine sample will be obtained. Free and continuous telephone access to the researcher will be available throughout the study. Control arm Mothers randomised to the control arm will meet with the project researcher when visiting the hospital for their first dating scan. The participant will not receive the 15 minute dietary advice session. A £10 supermarket voucher will be given to the participants. The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD questionnaire to inform them they will receive the second MD questionnaire and reply envelope for completion and return. A further supermarket voucher to the value of £10 will be sent to the participant on receipt of the completed form. Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher will contact participants by phone and arrange a home visit. When visited at home by the researcher, a third MD questionnaire and second FFQ will be completed and handed to the researcher and a urine sample will be obtained.
- Randomisation Allocation to the intervention or control arm will be via pre-randomised sealed envelopes, based on a predetermined random number allocation, restricted by recruitment site. This restricted randomisation will be carried out by an independent statistician.
- Follow-up Participants will be enrolled for a total of ~7 months (i.e. from 12-36 weeks of pregnancy).
Outcome measures
- Recruitment rate (i.e. the proportion of those invited to take part compared with the number of consenting women)
- Retention rate (i.e. the proportion of those starting the study to those finishing)
- Change in MD score from baseline to 24 and 36 weeks of pregnancy
- Change in oxidative stress and whole-body NO production
- Acceptability of dietary advice and diet modifications
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dietary support | Experimental | Behavioral: Dietary supportFace to face intervention plus subsequent telephone support |
| No dietary support | Placebo comparator | Behavioral: No dietary supportNo face to face intervention plus subsequent telephone support |
Who may qualify
- Ages
- 16 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Pregnant in first trimester
- Age 16 years and above
- One or more first degree blood relatives of the baby with atopic dermatitis(eczema), food allergy, allergic rhinitis (persistent or intermittent) or asthma
- Willing to give informed consent
Key exclusion criteria (4 listed)
- Age <16 years
- No first degree blood relatives of the baby with atopic dermatitis (eczema), food allergy, allergic rhinitis (persistent or intermittent) or asthma
- Recent (within the last 3 months) or current involvement in a dietary or supplementation trial
- Unable to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary supportFace to face intervention plus subsequent telephone support | Behavioural | Dietary support |
| No dietary supportNo face to face intervention or subsequent telephone support | Behavioural | No dietary support |
Primary outcome
Recruitment rate of pregnant mothers whose infants are at high risk of atopic disease.
Time frame: 4 months
1 secondary outcome
Mediterranean Diet score in pregnancy
Time frame: 12 and 24 weeks post-intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2017.
- Background: PubMed 23768094Sewell DA, Hammersley VS, Devereux G, Robertson A, Stoddart A, Weir C, Worth A, Sheikh A. Investigating the effectiveness of the Mediterranean diet in pregnant women for the primary prevention of asthma and allergy in high-risk infants: protocol for a pilot randomised controlled trial. Trials. 2013 Jun 14;14:173. doi: 10.1186/1745-6215-14-173.
- Background: PubMed 28211106Sewell DA, Hammersley VS, Robertson A, Devereux G, Stoddart A, Weir CJ, Worth A, Sheikh A. A pilot randomised controlled trial investigating a Mediterranean diet intervention in pregnant women for the primary prevention of allergic diseases in infants. J Hum Nutr Diet. 2017 Oct;30(5):604-614. doi: 10.1111/jhn.12469. Epub 2017 Feb 16.
- Individual participant dataSharing planned: No
Related trials for Allergy
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dean A. Sewell, PhD principal investigator
Heriot-Watt University
Aziz Sheikh, MBBS, MD study chair
University of Edinburgh
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary support and No dietary support in people with Allergy, run by Heriot-Watt University at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment rate of pregnant mothers whose infants are at high risk of atopic disease. (time frame: 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01634516, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2017.